Stuttgart - Delayed Quote EUR

Teva Pharmaceutical Industries Ltd (TEV.SG)

11.35

-1.30

(-10.28%)

At close: April 11 at 4:32:02 PM GMT+2

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.

Motley Fool 18 hours ago

PM

^GSPC

TEVA
Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President […]

Insider Monkey 2 days ago

TEVA

^GSPC

GLRE
Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

Teva Pharmaceutical Industries (NYSE:TEVA) recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients, an important step with potential market impact. Despite this positive development, Teva's share price recently declined 11% over the past week. This downward movement aligns with a broader market downturn of 12% amid heightened volatility and concerns regarding proposed tariffs on pharmaceuticals...

Simply Wall St. 4 days ago

TEVA

TEVJF
0.00%
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $13.94 as of April 7th. TEVA’s trailing and forward P/E were 872 and 5.37 respectively according to Yahoo Finance. After years […]

Insider Monkey 5 days ago

TEVA
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsun

GlobeNewswire 6 days ago

TEVA

TEVJF
0.00%
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva’s dedication to expanding access to innovat

GlobeNewswire 6 days ago

TEVA

TEVJF
0.00%
Teva announces presentation of survey study on TEV-‘749

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study evaluating TEV-‘749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-‘749, overall, including initiation regimen, monthly dosing schedu

TipRanks 12 days ago

TEVA

TEVJF
0.00%
Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA)stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade […]

Insider Monkey 12 days ago

TEVA
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY® (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trialTeva continues its commitment to generating clinical insights that help advance and support optimal treatment for individuals living w

GlobeNewswire 13 days ago

TEVA

TEVJF
0.00%
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

This is an expected part of investing, especially when it comes to growth stocks. Teva Pharmaceutical (NYSE: TEVA) is my worst-performing stock so far in 2025, down 27% in less than three months as of this writing. In fact, the company slightly beat expectations for both revenue and earnings.

Motley Fool 16 days ago

TEVA
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast o

GlobeNewswire 17 days ago

TEVA

TEVJF
0.00%
Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. Going forward, it is Te

GlobeNewswire 17 days ago

TEVA

TEVJF
0.00%
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.

Motley Fool 20 days ago

NVDA

PLTR

TEVA
Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?

We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other stocks that Jim Cramer discussed 12 months ago. During the latest episode of Mad Money, Jim Cramer advised his viewers to […]

Insider Monkey 22 days ago

TEVA
Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily 26 days ago

COLL

ANIP

HLN
Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed partially to recent regulatory milestones. The U.S. FDA's acceptance of a Supplemental New Drug Application for UZEDY, an extended-release injectable for maintenance treatment of bipolar I disorder, highlights Teva’s ongoing efforts in drug development. Additionally, the company's pursuit of biosimilars like AVT06, targeting eye disorders, underscores its strategic focus on...

Simply Wall St. 26 days ago

TEVA

TEVJF
0.00%
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Kerry Pharma's extensive logistics (fourth-party logistics, 4PL) distribution capabilities, this collaboration aims to enhance Teva's pharmaceutical distribution system in Hong Kong, Macau, and the Greater Bay Area, ensuring a stable supply of high-quality medical products. This initiative not only strengthens Teva's presence in Hong Kong, Macau, and

PR Newswire 30 days ago

TEVA

TEVJF
0.00%
Teva debuts global campaign encouraging people to get outside

The campaign will feature imagery and video creative across digital retail, owned media, out-of-home placements and paid social over all platforms.

Retail Dive last month

DECK

TEVA
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in March as follows: Barclays 27th Annual Global Healthcare ConferenceTuesday, March 11, 2025, at 8:00 am ETLeerink Partners Global Healthcare ConferenceWednesday, March 12, 2025, at 8:40 am ET To access a live webcast of the presentation, visit Teva’s Investor Relations web

GlobeNewswire last month

TEVA

TEVJF
0.00%
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]

Insider Monkey last month

AXSM

TEVA

Performance Overview

Return	TEV.SG	TA-125 (^TA125.TA)
YTD	-47.94%	+1.17%
1-Year	-12.02%	+25.54%
3-Year	+20.74%	+16.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Teva Pharmaceutical Industries Ltd (TEV.SG)

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Teva announces presentation of survey study on TEV-‘749

Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Teva Releases Q1 2025 Aide Memoire

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

Teva debuts global campaign encouraging people to get outside

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Performance Overview